News >

Triplet Shows Promise in Pediatric Kaposi Sarcoma

Jason Harris
Published: Thursday, Dec 14, 2017

Investigators working in Malawi found an association between the combination of vincristine, bleomycin, and etoposide (VBE) and improved quality of life (QoL), overall survival (OS), and event-free survival (EFS) in children with Kaposi sarcoma (KS).

On multivariate analysis, investigators found that only high numbers of treatments were significantly associated with a protective effect from death, loss to follow-up, or an event (hazard ratio [HR] 0.45; 95% CI, 0.30-0.69). For children who completed treatment, previous treatment for tuberculosis was associated with an increased risk for attrition (HR, 3.47; 95% CI, 0.94-12.75).
Macken M, Dale H, Moyo D, et al. Triple therapy of vincristine, bleomycin, and etoposide for children with Kaposi Sarcoma: Results of a study in Malawian children [published online October 8, 2017]. Pediatr Blood Cancer. doi: 10.1002/pbc.26841.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication